They started dosing 2/3 so they should see results for first patients by now...will be interesting for the next 30 days to pick up clues.<<
I'll take the other side of that speculation:
2016 ASCO key dates
It's fairly unusual for interim Phase 1 data to be presented, anyway. Though maybe less so the last few years. Still, I don't see how they make the deadline. Even a late breaker seems highly unlikely to me. I think ASH is more likely. It's possible they could present something before then at a relatively minor conference, but I wouldn't bank on that, either.
Edit: Abstract titles come out 4/20.
Regards, RockRat
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM